Company Active PLC

Company profile

Physiomics PLC

Physiomics | Physiomics - Oncology Drug Development | Pharmaceutical Consulting

Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.

CRN
04225086
Founded
2001
Age
25

Overview

Legal name
PHYSIOMICS PLC
Region
South East England
Registered address
MILTON PARK INNOVATION CENTRE 99 PARK DRIVE
MILTON PARK
ABINGDON
OXFORDSHIRE
ENGLAND
OX14 4RY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Physiomics PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

13 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

30 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

27 Oct
2023

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzM5ODA2MjcyOWFkaXF6a2N4 | Paper/PDF filed

Published 15 Aug 2024 07:53

30 May
2001

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2013
Funded years
2013, 2017, 2018, 2023
Age at first award
12 years

Projects

2023 Collaborative R&D Lead participant

PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool

1 Nov 2023 to 31 Mar 2026

Awarded
£137,376
Total cost £196,251

Patients with advanced cancers are often treated with chemotherapy which can reduce the effectiveness of the body's own immune system and leave patients exposed to infection. The manufacturers of chemotherapy drugs generally suggest using the same amount of drug for everybody who needs it, however, we know that because everyone is different, people end up...

2018 Feasibility Studies Lead participant

Prostate Cancer Chemotherapy Precision Dosing APP

1 Apr 2018 to 31 Mar 2019

Awarded
£68,115
Total cost £97,307

"Precision medicine heralds a new era of cancer care where each patient receives the right drug at the right dose and time specific to their needs. However, the practice of precision dosing is hampered by a lack of smart dosing algorithms. The choice of chemotherapy dose in the clinical practice is predominantly based on Body Surface Area (BSA) which is d...

2017 Feasibility Studies Lead participant

DECISION SUPPORT SYSTEMS FOR STRATIFIED CANCER TREATMENT

1 Feb 2017 to 31 Jan 2018

Awarded
£132,548
Total cost £189,354

Stratified medicine is a medical model in which patient group data are taken into account to tailor treatment. Various data, including pharmacogenomic data, are used to customise the treatment plan for these patient groups. In oncology, this treatment plan can involve chemotherapy, radiation and surgery. Deciding which treatments to use, and when to apply...

2013 Feasibility Studies Lead participant

Clinical version of the Physiomics Virtual Tumour

1 Jul 2013 to 31 Mar 2014

Awarded
£148,465
Total cost £197,954

Personalised medicine can be broken down into three key questions: which drugs do we give to a particular patient, how much and when? While many companies are seeking to address the first question, dosing and scheduling issues are poorly understood. Attrition rates in oncology remain high, part of the problem being that dosing and scheduling regimens are ...

Product types

Collaborative R&D Feasibility Studies